PSP Research »

Enliven Therapeutics shares owned by PSP Research

Quarter-by-quarter ownership of Enliven Therapeutics (ELVN) shares owned by PSP Research from 13F filings

Historical chart of PSP Research investment in Enliven Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Enliven Therapeutics held by PSP Research consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Enliven Therapeutics by PSP Research

Quarter filed Position value Share count Share price at filing
2026-03-31 $274k 7.0k 39.20

More positions owned by PSP Research

Ishares Tr 0-3 Mnth Treasry (SGOV)
Spdr Series Trust State Street Spd (XBI)
Sera Prognostics Class A Com (SERA)
Definium Therapeutics Com Shs (DFTX)
Tyra Biosciences (TYRA)
Ascendis Pharma A/s Sponsored Adr (ASND)
Pharvaris N V (PHVS)
Cytokinetics Com New (CYTK)
Royalty Pharma Shs Class A (RPRX)
Kymera Therapeutics (KYMR)
Halozyme Therapeutics (HALO)
Exelixis (EXEL)
Disc Medicine (IRON)
Ionis Pharmaceuticals (IONS)
Agios Pharmaceuticals (AGIO)

View all positions for PSP Research

Top funds holding Enliven Therapeutics

OrbiMed Advisors
FMR
Commodore Capital
Vestal Point Capital
Fairmount Funds Management
BlackRock
Polar Capital Holdings
VR Adviser
Vanguard Group
Point72 Asset Management
Novo A/S
Citadel Advisors
Capital Research Global Investors
State Street Corporation
Geode Capital Management

View all funds holding Enliven Therapeutics